Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 78 | 3,138 | 48% |
| 2020 | 76 | 2,941 | 50% |
| 2021 | 81 | 3,468 | 52% |
| 2022 | 71 | 3,372 | 53% |
| 2023 | 63 | 2,998 | 55% |
| 2024 | 57 | 2,787 | 56% |
| 2025 from claims | – | 2,835 2,602–3,000 | 56% |
| 2026 forecast | – | 2,886 2,539–3,330 | 56% |
| 2027 forecast | – | 2,922 2,498–3,482 | 56% |
| 2028 forecast | – | 2,959 2,469–3,623 | 56% |
| 2029 forecast | – | 2,996 2,447–3,757 | 57% |
| 2030 forecast | – | 3,033 2,430–3,887 | 57% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 44% of the cases CMS names in California; 32 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 90% inpatient hospital, 8% hospital outpatient, 2% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 19 | 661−4.1%/yr | −4.1%/yr | 0.9 | 2% | 740 in 2030+1.8%/yr |
| Washington | 14 | 622−9.6%/yr | −9.6%/yr | 0.8 | 5% | 540 in 2030−2.4%/yr |
| Colorado | 10 | 513−4.9%/yr | −4.9%/yr | 1.0 | 3% | 590 in 2030+2.5%/yr |
| Oregon | 9 | 416−2.9%/yr | −2.9%/yr | 1.0 | 3% | 440 in 2030+0.9%/yr |
| Utah | 7 | 330−1.7%/yr | −1.7%/yr | 1.5 | 5% | 420 in 2030+4.1%/yr |
| Nevada | 5 | 186−18%/yr | −18%/yr | 0.6 | 0% | 150 in 2030−3.1%/yr |
| Idaho | 4 | 149−11%/yr | −11%/yr | 0.7 | 1% | 200 in 2030+5.3%/yr |
| Wyoming | 2 | 118−11%/yr | −11%/yr | 1.1 | 0% | 110 in 2030−0.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 1,332 | 456,139+1.4%/yr | +1.4%/yr | 129.72.0× | 57% | 501,600 in 2030+1.6%/yr |
| Skin substitutes & wound grafts | 313 | 86,283+22%/yr | +22%/yr | 15.61.7× | 83% | 134,700 in 2030+7.7%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Bausch & Lomb leads with 38% of company spending on these surgeons in 2025, −10 pts on 2024.
In 2025, 17 companies reported engagement with California’s surgeons worth $598K in consulting, speaking, meals and travel tied to these products, about $10K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.